Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-12-2023 | Everolimus | Case report

Brentuximab-vedotin/everolimus/pembrolizumab

Lack of efficacy and pneumonitis

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Reuthner K, et al. Sustained complete remission with oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab. Oncology Research and Treatment 46 (Suppl.): 185, Oct 2023. Available from: URL: https://dx.doi.org/10.1159/000533576 [abstract] Reuthner K, et al. Sustained complete remission with oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab. Oncology Research and Treatment 46 (Suppl.): 185, Oct 2023. Available from: URL: https://​dx.​doi.​org/​10.​1159/​000533576 [abstract]
Metadata
Title
Brentuximab-vedotin/everolimus/pembrolizumab
Lack of efficacy and pneumonitis
Publication date
01-12-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-52015-y

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Midazolam

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Iopamidol

Case report

Ibrutinib

Case report

Glucose